Search
Displaying 141–150 of 543 for “Retinitis pigmentosa”
-
FFB-Funded Scientists Report on Nine Promising Translational Research Efforts
Research NewsThe Foundation Fighting Blindness has taken the translational challenge head on by investing more than $75 million in therapy-development projects with strong clinical-trial potential through its Translational Research Acceleration Program (TRAP), which includes Gund-Harrington Scholar Awards.
-
Researchers Find Mutation as Frequent Cause of RP in American Hispanics
Research NewsThe discovery can help genetic experts diagnose more patients with adRP, and it gives researchers a target for developing potential therapies.
-
Valproic Acid's Effect Too Small in One-Year Clinical Trial
Research NewsWhile a therapy for adRP will not emerge from the clinical trial, study investigators advanced development of a new outcome measure known as EZ Area to quickly and accurately evaluate potential therapies for RP in human studies.
-
A Change in Identity Might Someday Save Vision
Research NewsBy changing the identity of cells in the retina–namely rods–researchers may someday be able to slow or halt vision loss for those with retinitis pigmentosa (RP) and other related conditions.
-
Optogenetic Therapy Takes First Step Forward in Clinical Trial
Research NewsRetroSense’s optogenetic therapy is designed to restore vision to people who are completely blind from retinal degenerative diseases such as retinitis pigmentosa by bestowing light sensitivity to retinal ganglion cells, which survive after photoreceptors, the cells that make vision possible, are lost.
-
Pixium Vision Reports Progress in Development of Two Advanced Bionic Retina Systems
Research NewsBoth approaches show strong, near-term potential for providing meaningful vision to people who are otherwise blind from retinal diseases such as retinitis pigmentosa and age-related macular degeneration (AMD).
-
Research News
At VISIONS 2016, FFB’s national conference, the Foundation honored him with its Ed Gollob Board of Directors Award for breakthrough research conducted within the past year.
-
A Leap Forward: Spark Therapeutics Seeks FDA Approval for its Vision-Restoring Gene Therapy
Research NewsA Leap Forward: Spark Therapeutics Seeks FDA Approval for its Vision-Restoring Gene Therapy
-
Beacon Stories
An interview with Louis Posen, record label founder and retinitis pigmentosa patient.
-
CME — What It Is, and Why People with Retinal Diseases Should Know About It
Research NewsDr. Gerald Fishman discusses cystoid macular edema (CME), a potentially damaging accumulation of fluid in the retina affecting up to 32 percent of people with retinitis pigmentosa (RP).
